Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.
Ratings
3.3 / 5
3 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Christopher A. Viehbacher$33.1B
Market Cap • 25/07/20241997
(há 27 anos)
1991
(33 years ago)
NASDAQ
ListagemS&P500 Participant
Index Composite • 2024
Cambridge
Sede • Massachusetts8.725
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
BIIBSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.